In this edition:
KEYNOTE-A18: OS results
KEYNOTE-B21: pembrolizumab + adjuvant chemotherapy ± radiotherapy in high-risk endometrial cancer
PRIMA: final OS results
ATHENA-COMBO: first-line maintenance rucaparib + nivolumab vs. rucaparib monotherapy for ovarian cancer
ATALANTE: final 5-year OS results
TROPHAMET: first-line avelumab + methotrexate for low-risk gestational trophoblastic tumours
ICON9: maintenance olaparib ± cediranib in recurrent platinum-sensitive ovarian cancer
MoST-CIRCUIT: nivolumab + ipilimumab in advanced gynaecological clear-cell cancers
TROPION-PanTumor03: Dato-DXd monotherapy in endometrial or ovarian cancer
Sacituzumab tirumotecan in advanced endometrial or ovarian cancer
Please login below to download this issue (PDF)